These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 8929312)

  • 1. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
    Utech CI; Young CS; Winter PF
    Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
    Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
    Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
    van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
    Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
    Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
    Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
    Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
    Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
    Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging--initial findings.
    Stadnik TW; Everaert H; Makkat S; Sacré R; Lamote J; Bourgain C
    Eur Radiol; 2006 Oct; 16(10):2153-60. PubMed ID: 16670863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
    Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
    J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
    Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN
    J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
    Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer.
    Kumar R; Zhuang H; Schnall M; Conant E; Damia S; Weinstein S; Chandra P; Czerniecki B; Alavi A
    Nucl Med Commun; 2006 Mar; 27(3):231-6. PubMed ID: 16479242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy.
    Fehr MK; Hornung R; Varga Z; Burger D; Hess T; Haller U; Fink D; von Schulthess GK; Steinert HC
    Breast J; 2004; 10(2):89-93. PubMed ID: 15009033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.